Predicting success: Optimizing phase II ALS trials for the transition to phase III

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

(2013) Timothy M Miller et al.   LANCET NEUROLOGY

The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials

(2013) James D. Berry et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

A proposed staging system for amyotrophic lateral sclerosis

(2012) J. C. Roche et al.   BRAIN

Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency

(2012) Kambiz N. Alavian et al.   BRAIN RESEARCH

Factors affecting the diagnostic delay in amyotrophic lateral sclerosis

(2011) Eleonora Cellura et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis

(2011) Merit Cudkowicz et al.   NATURE MEDICINE

A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis

(2009) Robert M. Pascuzzi et al.   Amyotrophic Lateral Sclerosis

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

(2009) Sanne Piepers et al.   ANNALS OF NEUROLOGY

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III

(2009) Petra Kaufmann et al.   ANNALS OF NEUROLOGY

Latent Cluster Analysis of ALS Phenotypes Identifies Prognostically Differing Groups

(2009) Jeban Ganesalingam et al.   PLoS One

Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study

(2007) S Zoccolella et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Predictors of long survival in amyotrophic lateral sclerosis: A population-based study

(2007) Stefano Zoccolella et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES